In this cohort study of individuals with T2D and/or HF, we found that medication co-payment was independently associated with 12-month adherence to GLP1-RA and SGLT2i medications even after adjustment for sociodemographic and clinical factors. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.